Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

log into MY ENETS

ENETS Abstract Search

#1904 Treatment of Paragangliomas with Lutetium-177-Octreotate Based Peptide Receptor Radionuclide Therapy

Introduction: Paragangliomas (PGL) are a heterogeneous group of rare tumours that can express high numbers of somatostatin receptors on their cell surface and can be targeted with peptide receptor radionuclide therapy (PRRT) using the radiolabelled somatostatin analogue [lutetium-177-DOTA-Tyr3-]octreotate (177Lu-octreotate).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Smit Duijzentkunst D

Authors: Smit Duijzentkunst D, Kwekkeboom D,

Keywords: PRRT, paragangliomas,

#981 Parathyroid Hormone-Related Peptide (PTHrP) Secretion by Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET): Clinical Features, Diagnosis, Management, and Long-Term Follow-Up

Introduction: There are a few large series of patients with parathyroid hormone (PTH)-related protein (PTHrP) secreting neuroendocrine tumors (NETs) causing severe hypercalcemia.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Kamp K, Feelders R, De Rijke Y, Van Nederveen F, Kwekkeboom D,

Keywords: PTH, PTHrP, net, hypercalcemia,

#889 Delayed Haematological Toxicity in Patients Treated with 177Lu-octreotate Peptide Receptor Radiotherapy (PRRT) for Metastatic Neuroendocrine Tumors (NETs)

Introduction: PRRT is associated with a high tumor control rate and early toxicity seems acceptable (haematological grade 3-4 toxicity: 11.3%). Long-term monitoring of haematological toxicity is unavailable.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Hentic O, Lebtahi R, Kwekkeboom D, Fenaux P, Palazzo M,

Keywords: metastatic NET, PRRT, haematological toxicity,

#698 Feasability of a Dosimetry Guided Therapy Planning for Peptide Receptor Radionuclide Therapy with 177Lu-DOTA-Octreotate

Introduction: The efficacy and safety profile of PRRT can theoretically be optimized by planning each individual patient treatment on the absorbed dose to the critical organs and tumor lesions.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Krenning E, Erion J, Boesen-de Cock J, Kooij P, Kwekkeboom D,

Keywords: PRRT, dosimetry,